Developer docs
API playgroundTry for free, no card

Search company profiles

Healsun Biopharm

Full company profile

uuid0002dj5

Namestring
Healsun Biopharm
Legal namestring
杭州皓阳生物技术有限公司
Websiteurl
hs-biopharm.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Healsun Biopharm (杭州皓阳生物技术有限公司) is a privately held, pure-play biopharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in November 2015 in Hangzhou, China. The company provides end-to-end services for antibody, bispecific antibody, fusion protein, and antibody-drug conjugate (ADC) drugs, spanning early-stage drugability assessment through commercial-scale GMP manufacturing. Its service portfolio is anchored by the proprietary HaoYue® stable cell line platform (CHO-K1 host cell based, with global sub-licensing rights) and a Fut8-knockout ADCC-enhanced variant, complemented by upstream/downstream process development, ADC conjugation (over 1,300 projects delivered), analytical testing (CNAS-accredited), formulation development, customized medium development, and gene therapy AAV/mRNA services. Manufacturing infrastructure spans three advanced production bases in Shanghai and Hangzhou totaling 52,500 m², with current GMP clinical lines (5,000 m² large molecule + 500 m² ADC) and a commercial-scale MFG2 facility (6×2,000 L antibody + 1×500 L ADC) under construction for end-2026 commissioning.

The company serves domestic and international biopharma companies developing innovative biologics and biosimilars, with over 150 customers served and 40+ IND-stage projects delivered to date. Notable clients include Beijing Lepu Pharmaceutical (China's first NMPA-approved dulaglutide biosimilar, full DNA-to-IND service), Ginkgo Pharma, Aikelian Bio, Fanli Bio, and Betta Pharma. Healsun is differentiated as a pure-play CDMO with no proprietary pipeline, eliminating competitive conflicts with clients. The company is fee-for-service, pricing projects on a per-project or milestone basis tied to molecule complexity and development stage. Go-to-market is B2B enterprise field sales with a dedicated BD team, supplemented by industry conferences, a technical thought-leadership platform (HaoQiXing/HaoXueBuJue), and an international market specialist targeting Europe and the US following the December 2024 EU QP audit pass.

The company has raised approximately USD 100M+ across multiple funding rounds: CNY 50M (2018 strategic), CNY 80M+ (A-round, April 2021, Yipu Capital + Haibang Investment), CNY ~250M (B-round, August 2022, led by Shanghai Biopharmaceutical Fund), undisclosed B+ round (October 2023), and a new equity round (November 2025). It has been recognized as a National High-Tech Enterprise, a 2022 Zhejiang Specialized and Sophisticated SME, and holds CNAS laboratory accreditation, ISO 9001:2015, and EU GMP QP certification. Headcount has grown from 4 founders to 220+ employees as of March 2023 across Hangzhou headquarters and a Shanghai R&D subsidiary opened in May 2023.

Short descriptiontext

Healsun Biopharm is a Hangzhou-based pure-play biopharmaceutical CDMO providing end-to-end antibody, fusion protein, and ADC drug development and GMP manufacturing services for domestic and international biopharma companies, anchored by its proprietary HaoYue stable cell line platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHangzhou, China
HQ citystring
Hangzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical CDMO services, antibody drug development, stable cell line platform, ADC contract manufacturing, GMP biologics manufacturing
Industry3 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
SECONDARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical CDMO Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Service Fees (Full-Service Contract Development)
TypeProfessional Services
Description

Fee-for-service CDMO model covering the entire biologics development lifecycle: early drug developability assessment, stable cell line construction, process development (upstream/downstream/ADC), analytical method development, GMP clinical sample production, and commercial manufacturing. Revenue recognized as projects are executed and milestones are met. Core revenue stream for the pure-play biologics CDMO.

hs-biopharm.com
2Media and Reagent Customization Services
TypeProfessional Services
Description

Customized development and supply of cell culture media and feed for biologics manufacturing, including chemically defined培养基. Revenue from medium formulation customization services.

hs-biopharm.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Healsun Biopharm is a pure-play biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for antibody, bispecific antibody, fusion protein, and ADC drugs. Services span early-stage drugability assessment, stable cell line construction (HaoYue platform), upstream/downstream process development, analytical testing, ADC conjugation, GMP clinical sample production, and commercial-scale manufacturing under FDA/EMA/NMPA cGMP standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • ≥5g/L expression guarantee for symmetric mAb/bisAb stable cell lines; 2024 average exceeded 6.8g/L
+8 more records
Product overview1 text field

Healsun Biopharm is a pure-play biopharmaceutical CDMO offering end-to-end services for antibody, fusion protein, and ADC (antibody-drug conjugate) drugs from early-stage drugability assessment through commercial-scale GMP manufacturing. The company operates an integrated service portfolio anchored by the HaoYue® stable cell line platform (including the Fut8-KO ADCC-enhanced variant), complemented by upstream/downstream process development, ADC conjugation, analytical testing (CNAS/ISO 9001 certified), customized medium development, and formulation development services. The company maintains GMP clinical sample production lines for both large molecules (5,000 m²) and ADCs (500 m²), with commercial-scale manufacturing capacity under construction (6×2,000L). Services also include a gene therapy AAV/mRNA CRO platform and a catalog of research-grade tool proteins sold via an online shop.

Product and service18 records
1HaoYue® Stable Cell Line Platform (皓越)
CategoryPlatform Service
Description

High-expression stable cell line development platform using commercially authorized CHO-K1 host cells combined with proprietary plasmid systems and cell line screening protocols. Delivers symmetric monoclonal/bispecific antibodies at ≥5 g/L (2024 average >6.8 g/L) within 10-12 weeks for biopharma clients developing antibody drugs.

2ADCC-Enhanced (Fut8-KO) Stable Cell Line Platform
CategoryPlatform Service
Description

Fut8 knockout CHO-K1 cell line platform built on HaoYue®, enabling production of low-fucosylation antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. Fucose content stably below 1.5%.

3Host Cell Commercial Licensing (CHO-K1)
CategoryLicensing Service
Description

Commercial licensing of CHO-K1 host cells for stable cell line development, with global sublicensing rights. Provided to biopharma clients building or expanding their own cell line development capabilities.

4Drugability Assessment Service (成药性评估)
CategoryDiscovery / Early Research Service
Description

Early-stage systematic drugability assessment covering sequence analysis, ProA affinity purification, high-polymer detection (SEC-HPLC), hydrophobicity (HIC-HPLC), Tm value, MS-based PTM analysis, and pre-stability studies for candidate antibody and recombinant protein molecules.

5Upstream Process Development (上游工艺开发)
CategoryCMC Process Development Service
Description

QbD-based upstream process development using 16×3L and 4×15L bioreactors, ATF2 for perfusion/CFB, and 24 deep-well plates for high-throughput optimization. Supports glycosylation modulation and bispecific antibody fragment ratio control.

6Downstream Process Development (下游工艺开发)
CategoryCMC Process Development Service
Description

Antibody and recombinant protein purification process development using AKTA Pure/Avant, including chromatography, depth filtration, ultrafiltration, virus clearance (low pH, S/D, nanofiltration), and scale-down model process characterization. ~70% overall recovery within 8-12 weeks.

7Formulation Development (制剂处方工艺开发)
CategoryCMC Process Development Service
Description

Formulation development for monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs covering liquid and lyophilized dosage forms, including high-concentration formulation, stability studies, and packaging material compatibility per ICH and pharmacopeial standards.

8Customized Medium Development (培养基定制开发)
CategoryCMC Process Development Service
Description

Customized basal media, feed media, and perfusion media development for CHO cells using proprietary base formulation libraries; chemically defined, animal-free, no protein/peptides. Currently used in NMPA and FDA regulatory filings.

9ADC Platform (ADC药物平台)
CategoryADC Service Platform
Description

End-to-end antibody-drug conjugate services from early discovery through GMP manufacturing, including ADC drug screening, conjugation process development (random and site-specific), purification, analysis, and lyophilization. Over 1,300 conjugation projects delivered across 10+ small molecule linkers; GMP conjugation scale 20L-500L.

10GMP Clinical Sample Production — Large Molecule (临床样品生产-大分子)
CategoryGMP Manufacturing Service
Description

cGMP-compliant (FDA/EMA/NMPA) manufacturing of clinical-stage antibody drug substance and drug product on 5,000 m² lines producing 3,000g bulk drug substance per batch and 10,000 vials per filling batch. Antibody DNA to toxicology batch delivered in 7 months; Pre-IND package in 12 months.

11GMP Clinical Sample Production — ADC (ADC临床样品生产)
CategoryGMP Manufacturing Service
Description

Independent 500 m² ADC cGMP lines (FDA/EMA/NMPA) with OEB5-level negative pressure isolators and 50/100/150L single-use bioreactors. Annual capacity of 50 batches at 1,500g ADC per batch. Antibody DNA to ADC toxicology batch in 8 months; Pre-IND package in 13 months.

12Commercial Manufacturing — PC/PV (商业化生产)
CategoryCommercial Manufacturing Service
Description

Process characterization (PC) and process validation (PV) services for commercial manufacturing readiness. Commercial lines under construction: 6×2,000L antibody bioreactors and 1×500L ADC conjugation line.

13Industrialization Service (产业化)
CategoryCommercial Manufacturing Service
Description

Commercial-scale drug substance and drug product manufacturing: 6×2,000L antibody lines, 1×200L + 1×500L ADC lines, 100,000 vials/batch antibody vial line, 37,000 vials/batch antibody lyophilization line, 160,000 prefilled syringes/batch, 30,000 vials/batch ADC lyophilization line.

14Protein Engineering — Antibody Humanization (蛋白工程-人源化)
CategoryDiscovery / Early Research Service
Description

Antibody humanization design reducing immunogenicity of murine monoclonals. Delivers humanization design, protein preparation, and affinity screening in 5 weeks with off-rate ranking within 3× of chimeric antibody.

15Yeast Cell Surface Display Service (酵母细胞表面展示)
CategoryDiscovery / Early Research Service
Description

Yeast surface display technology for antibody sequence optimization including affinity maturation, cross-reactivity improvement, hydrophobicity improvement, and PTM site removal. 8 weeks from plasmid construction to protein delivery using HEK293/CHO transient expression.

16Analytical Support (理化/生化分析/蛋白表征)
CategoryAnalytical Service
Description

Comprehensive analytical services including SEC-HPLC, CE-SDS, icIEF, HIC-HPLC, HTRF, ELISA, cell-based potency, and LC-MS characterization. CNAS-accredited laboratory compliant with ISO 9001:2015.

17Tool Proteins (工具蛋白)
CategoryResearch Reagent Product
Description

Catalog of research-grade recombinant proteins modeled after marketed biologics (Trastuzumab, Bevacizumab, Pembrolizumab, Rituximab, etc.) available at gram and milligram scales. Sold via online shop at shop.hs-biopharm.com as research reagents and reference standards.

18Gene Therapy AAV/mRNA CRO Service (基因治疗)
CategoryGene Therapy Service
Description

Full-process AAV/mRNA CRO services for gene therapy, including vector design, process development, and analytical support.

Scale indicator20 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Ginkgo Pharma (劲方医药)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to post-marketing production services. Ginkgo Pharma is a clinical-stage biotech company developing innovative small molecule drugs.

hs-biopharm.com
2Aikelian Bio (艾科联生物)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Aikelian Bio is a biotech company developing innovative biologics.

hs-biopharm.com
3Fanli Bio (帆礼生物)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Fanli Bio is an innovative biologics company.

hs-biopharm.com
4Betta Pharma (贝达药业)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Signed ecosystem strategic cooperation agreement at 10th anniversary ceremony (November 2025), leveraging 'dragon head + professional empowerment' model to activate industry innovation. Betta Pharma is a leading Chinese innovative pharmaceutical company listed on Shenzhen Stock Exchange (SZ:300558).

hs-biopharm.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Genscript ProBio is the biologics CDMO arm of Genscript Biotech, providing cell line development, process development, and GMP manufacturing for antibodies, recombinant proteins, plasmids, and viral vectors. It is a direct peer to Healsun in cell line platforms and antibody CDMO services, with broader gene therapy capabilities.

TypeDirect peer
Description

WuXi XDC is the dedicated ADC-focused CDMO spun out from WuXi Biologics, offering integrated discovery, development, and manufacturing services for antibody-drug conjugates. It is the most direct ADC-specific competitor to Healsun's 1,300+ conjugation project platform, with larger scale, established global clients, and broader payload/linker coverage.

3BiBo Biologics
TypeEmerging player
Description

BiBo Biologics (Shanghai) is an emerging Chinese biologics CDMO providing cell line development, process development, and GMP manufacturing services for antibodies and recombinant proteins. Comparable to Healsun as an emerging Chinese pure-play biologics CDMO targeting similar mid-sized biotech clients.

4MabPlex International
TypeDirect peer
Description

MabPlex International is a Chinese biologics CDMO specializing in antibody and recombinant protein development and manufacturing, including ADC services. Closely comparable to Healsun as a mid-sized pure-play biologics CDMO with cell line development, process development, and GMP manufacturing for both antibodies and ADCs.

5DoBi Biologics
TypeEmerging player
Description

DoBi Biologics is an emerging Chinese CDMO with capabilities in cell line construction, process development, and GMP manufacturing for antibodies and recombinant proteins. Comparable to Healsun as a smaller emerging Chinese biologics CDMO serving similar early-to-mid-stage biotech clients.

TypeDirect peer
Description

WuXi Biologics is China's largest and the world's leading open-access biologics CDMO, offering end-to-end services from cell line development to commercial manufacturing. It is the most direct competitor to Healsun, with overlapping antibody, bispecific, and ADC capabilities at significantly larger scale (over 10,000 employees, multiple global sites). Both companies target the same biopharma client base with fee-for-service biologics CDMO offerings.

TypeBroad incumbent
Description

Pharmaron is a global CRO/CDMO with integrated biologics capabilities as part of a broader service portfolio spanning small molecule, biologics, and gene therapy. Comparable to Healsun in biologics and ADC offerings, but operates as part of a much larger full-service platform with greater scale and geographic reach.

8Asymchem Laboratories
TypeBroad incumbent
Description

Asymchem is a leading Chinese CDMO historically focused on small-molecule APIs that has been expanding into biologics and oligonucleotide CDMO services. It is a broad incumbent in the CDMO space with overlapping biologics CDMO ambitions and substantially larger scale than Healsun.

TypeBroad incumbent
Description

Hangzhou Tigermed is one of China's largest clinical CROs that has expanded into biopharmaceutical CDMO and laboratory services. Comparable as a Chinese-based biopharma services provider but with a much broader portfolio spanning clinical trials, biologics CDMO, and lab services.

10Porton Biologics
TypeDirect peer
Description

Porton Biologics is the biologics CDMO subsidiary of Porton Pharma, offering cell line construction, process development, and GMP manufacturing for monoclonal antibodies, bispecifics, fusion proteins, and ADCs. Closely comparable to Healsun as a Chinese biologics CDMO with end-to-end antibody and ADC services targeting similar customer segments.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Healsun Biopharm

Biopharmaceutical CDMO Serviceshs-biopharm.com

Healsun Biopharm is a Hangzhou-based pure-play biopharmaceutical CDMO providing end-to-end antibody, fusion protein, and ADC drug development and GMP manufacturing services for domestic and international biopharma companies, anchored by its proprietary HaoYue stable cell line platform.

What Healsun Biopharm does

Healsun Biopharm (杭州皓阳生物技术有限公司) is a privately held, pure-play biopharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in November 2015 in Hangzhou, China. The company provides end-to-end services for antibody, bispecific antibody, fusion protein, and antibody-drug conjugate (ADC) drugs, spanning early-stage drugability assessment through commercial-scale GMP manufacturing. Its service portfolio is anchored by the proprietary HaoYue® stable cell line platform (CHO-K1 host cell based, with global sub-licensing rights) and a Fut8-knockout ADCC-enhanced variant, complemented by upstream/downstream process development, ADC conjugation (over 1,300 projects delivered), analytical testing (CNAS-accredited), formulation development, customized medium development, and gene therapy AAV/mRNA services. Manufacturing infrastructure spans three advanced production bases in Shanghai and Hangzhou totaling 52,500 m², with current GMP clinical lines (5,000 m² large molecule + 500 m² ADC) and a commercial-scale MFG2 facility (6×2,000 L antibody + 1×500 L ADC) under construction for end-2026 commissioning.

The company serves domestic and international biopharma companies developing innovative biologics and biosimilars, with over 150 customers served and 40+ IND-stage projects delivered to date. Notable clients include Beijing Lepu Pharmaceutical (China's first NMPA-approved dulaglutide biosimilar, full DNA-to-IND service), Ginkgo Pharma, Aikelian Bio, Fanli Bio, and Betta Pharma. Healsun is differentiated as a pure-play CDMO with no proprietary pipeline, eliminating competitive conflicts with clients. The company is fee-for-service, pricing projects on a per-project or milestone basis tied to molecule complexity and development stage. Go-to-market is B2B enterprise field sales with a dedicated BD team, supplemented by industry conferences, a technical thought-leadership platform (HaoQiXing/HaoXueBuJue), and an international market specialist targeting Europe and the US following the December 2024 EU QP audit pass.

The company has raised approximately USD 100M+ across multiple funding rounds: CNY 50M (2018 strategic), CNY 80M+ (A-round, April 2021, Yipu Capital + Haibang Investment), CNY ~250M (B-round, August 2022, led by Shanghai Biopharmaceutical Fund), undisclosed B+ round (October 2023), and a new equity round (November 2025). It has been recognized as a National High-Tech Enterprise, a 2022 Zhejiang Specialized and Sophisticated SME, and holds CNAS laboratory accreditation, ISO 9001:2015, and EU GMP QP certification. Headcount has grown from 4 founders to 220+ employees as of March 2023 across Hangzhou headquarters and a Shanghai R&D subsidiary opened in May 2023.

Healsun Biopharm firmographics

Firmographics
Name
Healsun Biopharm
Legal name
杭州皓阳生物技术有限公司
Website
https://hs-biopharm.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Healsun Biopharm is a Hangzhou-based pure-play biopharmaceutical CDMO providing end-to-end antibody, fusion protein, and ADC drug development and GMP manufacturing services for domestic and international biopharma companies, anchored by its proprietary HaoYue stable cell line platform.
Ownership category
akta.pro rank

Healsun Biopharm industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
SECONDARYHLAAAAAD
Fusion Proteins & Fc-Engineered Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Biopharmaceutical CDMO services
  • Antibody drug development
  • Stable cell line platform
  • ADC contract manufacturing
  • GMP biologics manufacturing

Where Healsun Biopharm is headquartered

Location

Headquarters

HQ city
Hangzhou
HQ country
China
HQ region
Asia

Offices4 records

Markets served

Healsun Biopharm business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CDMO Service Fees (Full-Service Contract Development): Fee-for-service CDMO model covering the entire biologics development lifecycle: early drug developability assessment, stable cell line construction, process development (upstream/downstream/ADC), analytical method development, GMP clinical sample production, and commercial manufacturing. Revenue recognized as projects are executed and milestones are met. Core revenue stream for the pure-play biologics CDMO.
  2. Media and Reagent Customization Services: Customized development and supply of cell culture media and feed for biologics manufacturing, including chemically defined培养基. Revenue from medium formulation customization services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Healsun Biopharm product offering

Product offering

Core offering

Healsun Biopharm is a pure-play biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for antibody, bispecific antibody, fusion protein, and ADC drugs. Services span early-stage drugability assessment, stable cell line construction (HaoYue platform), upstream/downstream process development, analytical testing, ADC conjugation, GMP clinical sample production, and commercial-scale manufacturing under FDA/EMA/NMPA cGMP standards.

Product overview

Healsun Biopharm is a pure-play biopharmaceutical CDMO offering end-to-end services for antibody, fusion protein, and ADC (antibody-drug conjugate) drugs from early-stage drugability assessment through commercial-scale GMP manufacturing. The company operates an integrated service portfolio anchored by the HaoYue® stable cell line platform (including the Fut8-KO ADCC-enhanced variant), complemented by upstream/downstream process development, ADC conjugation, analytical testing (CNAS/ISO 9001 certified), customized medium development, and formulation development services. The company maintains GMP clinical sample production lines for both large molecules (5,000 m²) and ADCs (500 m²), with commercial-scale manufacturing capacity under construction (6×2,000L). Services also include a gene therapy AAV/mRNA CRO platform and a catalog of research-grade tool proteins sold via an online shop.

Differentiator

Problem solved

Functional benefit

Products and services

  • HaoYue® Stable Cell Line Platform (皓越) High-expression stable cell line development platform using commercially authorized CHO-K1 host cells combined with proprietary plasmid systems and cell line screening protocols. Delivers symmetric monoclonal/bispecific antibodies at ≥5 g/L (2024 average >6.8 g/L) within 10-12 weeks for biopharma clients developing antibody drugs.
  • ADCC-Enhanced (Fut8-KO) Stable Cell Line Platform Fut8 knockout CHO-K1 cell line platform built on HaoYue®, enabling production of low-fucosylation antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. Fucose content stably below 1.5%.
  • Host Cell Commercial Licensing (CHO-K1) Commercial licensing of CHO-K1 host cells for stable cell line development, with global sublicensing rights. Provided to biopharma clients building or expanding their own cell line development capabilities.
  • Drugability Assessment Service (成药性评估) Early-stage systematic drugability assessment covering sequence analysis, ProA affinity purification, high-polymer detection (SEC-HPLC), hydrophobicity (HIC-HPLC), Tm value, MS-based PTM analysis, and pre-stability studies for candidate antibody and recombinant protein molecules.
  • Upstream Process Development (上游工艺开发) QbD-based upstream process development using 16×3L and 4×15L bioreactors, ATF2 for perfusion/CFB, and 24 deep-well plates for high-throughput optimization. Supports glycosylation modulation and bispecific antibody fragment ratio control.
  • Downstream Process Development (下游工艺开发) Antibody and recombinant protein purification process development using AKTA Pure/Avant, including chromatography, depth filtration, ultrafiltration, virus clearance (low pH, S/D, nanofiltration), and scale-down model process characterization. ~70% overall recovery within 8-12 weeks.
  • Formulation Development (制剂处方工艺开发) Formulation development for monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs covering liquid and lyophilized dosage forms, including high-concentration formulation, stability studies, and packaging material compatibility per ICH and pharmacopeial standards.
  • Customized Medium Development (培养基定制开发) Customized basal media, feed media, and perfusion media development for CHO cells using proprietary base formulation libraries; chemically defined, animal-free, no protein/peptides. Currently used in NMPA and FDA regulatory filings.
  • ADC Platform (ADC药物平台) End-to-end antibody-drug conjugate services from early discovery through GMP manufacturing, including ADC drug screening, conjugation process development (random and site-specific), purification, analysis, and lyophilization. Over 1,300 conjugation projects delivered across 10+ small molecule linkers; GMP conjugation scale 20L-500L.
  • GMP Clinical Sample Production — Large Molecule (临床样品生产-大分子) cGMP-compliant (FDA/EMA/NMPA) manufacturing of clinical-stage antibody drug substance and drug product on 5,000 m² lines producing 3,000g bulk drug substance per batch and 10,000 vials per filling batch. Antibody DNA to toxicology batch delivered in 7 months; Pre-IND package in 12 months.
  • GMP Clinical Sample Production — ADC (ADC临床样品生产) Independent 500 m² ADC cGMP lines (FDA/EMA/NMPA) with OEB5-level negative pressure isolators and 50/100/150L single-use bioreactors. Annual capacity of 50 batches at 1,500g ADC per batch. Antibody DNA to ADC toxicology batch in 8 months; Pre-IND package in 13 months.
  • Commercial Manufacturing — PC/PV (商业化生产) Process characterization (PC) and process validation (PV) services for commercial manufacturing readiness. Commercial lines under construction: 6×2,000L antibody bioreactors and 1×500L ADC conjugation line.
  • Industrialization Service (产业化) Commercial-scale drug substance and drug product manufacturing: 6×2,000L antibody lines, 1×200L + 1×500L ADC lines, 100,000 vials/batch antibody vial line, 37,000 vials/batch antibody lyophilization line, 160,000 prefilled syringes/batch, 30,000 vials/batch ADC lyophilization line.
  • Protein Engineering — Antibody Humanization (蛋白工程-人源化) Antibody humanization design reducing immunogenicity of murine monoclonals. Delivers humanization design, protein preparation, and affinity screening in 5 weeks with off-rate ranking within 3× of chimeric antibody.
  • Yeast Cell Surface Display Service (酵母细胞表面展示) Yeast surface display technology for antibody sequence optimization including affinity maturation, cross-reactivity improvement, hydrophobicity improvement, and PTM site removal. 8 weeks from plasmid construction to protein delivery using HEK293/CHO transient expression.
  • Analytical Support (理化/生化分析/蛋白表征) Comprehensive analytical services including SEC-HPLC, CE-SDS, icIEF, HIC-HPLC, HTRF, ELISA, cell-based potency, and LC-MS characterization. CNAS-accredited laboratory compliant with ISO 9001:2015.
  • Tool Proteins (工具蛋白) Catalog of research-grade recombinant proteins modeled after marketed biologics (Trastuzumab, Bevacizumab, Pembrolizumab, Rituximab, etc.) available at gram and milligram scales. Sold via online shop at shop.hs-biopharm.com as research reagents and reference standards.
  • Gene Therapy AAV/mRNA CRO Service (基因治疗) Full-process AAV/mRNA CRO services for gene therapy, including vector design, process development, and analytical support.

Quantifiable outcome

  • ≥5g/L expression guarantee for symmetric mAb/bisAb stable cell lines; 2024 average exceeded 6.8g/L
  • +8 more outcomes

Companies that use Healsun Biopharm

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Healsun Biopharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Healsun Biopharm partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Ginkgo Pharma (劲方医药)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to post-marketing production services. Ginkgo Pharma is a clinical-stage biotech company developing innovative small molecule drugs.
  • Aikelian Bio (艾科联生物)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Aikelian Bio is a biotech company developing innovative biologics.
  • Fanli Bio (帆礼生物)coreStrategic or Co-development Partner · 1 November 2025Signed project cooperation agreement at 10th anniversary ceremony (November 2025), covering Pre-CMC to上市后生产. Fanli Bio is an innovative biologics company.
  • Betta Pharma (贝达药业)coreStrategic or Co-development Partner · 1 November 2025Signed ecosystem strategic cooperation agreement at 10th anniversary ceremony (November 2025), leveraging 'dragon head + professional empowerment' model to activate industry innovation. Betta Pharma is a leading Chinese innovative pharmaceutical company listed on Shenzhen Stock Exchange (SZ:300558).

Scale indicators20 records

Recent moves11 records

Expansion highlights6 records

Healsun Biopharm competitors and assessment

Company assessment

Direct peers

  • Genscript ProBio: Genscript ProBio is the biologics CDMO arm of Genscript Biotech, providing cell line development, process development, and GMP manufacturing for antibodies, recombinant proteins, plasmids, and viral vectors. It is a direct peer to Healsun in cell line platforms and antibody CDMO services, with broader gene therapy capabilities.
  • WuXi XDC: WuXi XDC is the dedicated ADC-focused CDMO spun out from WuXi Biologics, offering integrated discovery, development, and manufacturing services for antibody-drug conjugates. It is the most direct ADC-specific competitor to Healsun's 1,300+ conjugation project platform, with larger scale, established global clients, and broader payload/linker coverage.
  • MabPlex International: MabPlex International is a Chinese biologics CDMO specializing in antibody and recombinant protein development and manufacturing, including ADC services. Closely comparable to Healsun as a mid-sized pure-play biologics CDMO with cell line development, process development, and GMP manufacturing for both antibodies and ADCs.
  • WuXi Biologics: WuXi Biologics is China's largest and the world's leading open-access biologics CDMO, offering end-to-end services from cell line development to commercial manufacturing. It is the most direct competitor to Healsun, with overlapping antibody, bispecific, and ADC capabilities at significantly larger scale (over 10,000 employees, multiple global sites). Both companies target the same biopharma client base with fee-for-service biologics CDMO offerings.
  • Porton Biologics: Porton Biologics is the biologics CDMO subsidiary of Porton Pharma, offering cell line construction, process development, and GMP manufacturing for monoclonal antibodies, bispecifics, fusion proteins, and ADCs. Closely comparable to Healsun as a Chinese biologics CDMO with end-to-end antibody and ADC services targeting similar customer segments.

Emerging players

  • BiBo Biologics: BiBo Biologics (Shanghai) is an emerging Chinese biologics CDMO providing cell line development, process development, and GMP manufacturing services for antibodies and recombinant proteins. Comparable to Healsun as an emerging Chinese pure-play biologics CDMO targeting similar mid-sized biotech clients.
  • DoBi Biologics: DoBi Biologics is an emerging Chinese CDMO with capabilities in cell line construction, process development, and GMP manufacturing for antibodies and recombinant proteins. Comparable to Healsun as a smaller emerging Chinese biologics CDMO serving similar early-to-mid-stage biotech clients.

Broad incumbents

  • Pharmaron Biologics: Pharmaron is a global CRO/CDMO with integrated biologics capabilities as part of a broader service portfolio spanning small molecule, biologics, and gene therapy. Comparable to Healsun in biologics and ADC offerings, but operates as part of a much larger full-service platform with greater scale and geographic reach.
  • Asymchem Laboratories: Asymchem is a leading Chinese CDMO historically focused on small-molecule APIs that has been expanding into biologics and oligonucleotide CDMO services. It is a broad incumbent in the CDMO space with overlapping biologics CDMO ambitions and substantially larger scale than Healsun.
  • Hangzhou Tigermed: Hangzhou Tigermed is one of China's largest clinical CROs that has expanded into biopharmaceutical CDMO and laboratory services. Comparable as a Chinese-based biopharma services provider but with a much broader portfolio spanning clinical trials, biologics CDMO, and lab services.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Healsun Biopharm compliance and trust

Trust signal

Compliance5 records

Healsun Biopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Healsun Biopharm leadership team

Management profile

Number of profiles

Profiles3 records

Healsun Biopharm subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Healsun Biopharm funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Healsun Biopharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healsun Biopharm

What does Healsun Biopharm do?

Healsun Biopharm is a pure-play biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for antibody, bispecific antibody, fusion protein, and ADC drugs. Services span early-stage drugability assessment, stable cell line construction (HaoYue platform), upstream/downstream process development, analytical testing, ADC conjugation, GMP clinical sample production, and commercial-scale manufacturing under FDA/EMA/NMPA cGMP standards.

Is Healsun Biopharm a public or private company?

Healsun Biopharm is a private company. It is classified as venture growth investor backed and is currently operating.

When was Healsun Biopharm founded?

Healsun Biopharm was founded in 2015. It employs 1 to 10 people.

Where is Healsun Biopharm based?

Healsun Biopharm is headquartered in Hangzhou, China, in the Asia region.

How does Healsun Biopharm make money?

Two revenue lines are on record. CDMO Service Fees (Full-Service Contract Development) is the primary driver. The others are media and Reagent Customization Services.

Who are Healsun Biopharm's main competitors?

Direct peers on record are Genscript ProBio, WuXi XDC, MabPlex International, WuXi Biologics and Porton Biologics. Emerging players are BiBo Biologics and DoBi Biologics. Broad incumbents are Pharmaron Biologics, Asymchem Laboratories and Hangzhou Tigermed.

Does Healsun Biopharm have an API?

No public API is recorded for Healsun Biopharm.

What industry is Healsun Biopharm in?

Healsun Biopharm's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales